2.01
-0.09(-4.29%)
Currency In USD
| Previous Close | 2.1 |
| Open | 2.06 |
| Day High | 2.16 |
| Day Low | 1.99 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 199,157 |
| Average Volume | 1.49M |
| Market Cap | 20.93M |
| PE | -0.5 |
| EPS | -3.99 |
| Moving Average 50 Days | 2.25 |
| Moving Average 200 Days | 2.23 |
| Change | -0.09 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $19.8 as of September 29, 2025 at a share price of $2.01. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $299.11 as of September 29, 2025 at a share price of $2.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Highlights Data in Multiple Presentations at EASD
GlobeNewswire Inc.
Sep 19, 2025 11:24 AM GMT
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in multiple SAB presentations and
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire Inc.
Sep 03, 2025 8:05 PM GMT
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyt
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved ali